High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.
about
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerUpdate on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsThird-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerThird-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.MET/HGF pathway activation as a paradigm of resistance to targeted therapies.Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyOvercoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report.Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report.Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.Third generation EGFR TKIs: current data and future directions.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
P2860
Q28067777-06F47A41-3D52-4A52-9640-9D965D5F23B7Q28069708-C9123DF6-BA6E-492A-98E6-076436A99327Q33740707-91BA5DE3-49EC-4897-BE93-188352744CB8Q34550460-C8017974-32B9-46C5-A57B-29D997D1A67DQ37597850-4C80D687-AA45-4ACB-A60A-961765DDC3D9Q37660829-15689C98-949D-4B94-971D-74DDCE7D11F6Q38598893-770EB55F-D24F-496B-8A5A-32B4550B62ABQ38682189-76DBFDAA-C47F-4323-A44E-267969F1E47DQ42363020-157187B8-DE56-4F25-AC87-3F4F7523CFFBQ45983599-6A17EEE3-EDA9-4EC5-8648-F283DB919027Q47146662-F92FFC75-516E-4BCB-9E55-0E28F5E8F515Q47814631-1FCF0B3D-2C86-4F8B-9F0B-82C456E0CFB0Q48091584-828B4FF3-F101-4C6A-820D-41C028837FCAQ49643911-0B529DF3-6118-4626-92CF-F91289776578Q49887956-D839AE9D-F055-4F6F-8658-88EE38B6BD8BQ50345931-B286AF60-A48B-4D65-94D3-F94846738D03Q51741619-8BC957D4-42A6-4752-90EC-EF4C97658BDFQ52312436-A4D73C14-559E-4092-BF77-AB9EB8F733DCQ52597593-8108FC34-098C-4571-B83C-1476FCD08E69Q55191884-FC6F641C-5219-4815-A813-98683FED9E67Q57177486-8D7B2EC9-BA10-466D-955A-1CBF40FB504F
P2860
High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
High MET amplification level a ...... post-osimertinib progression.
@en
High MET amplification level as a resistance mechanism to osimertinib
@nl
type
label
High MET amplification level a ...... post-osimertinib progression.
@en
High MET amplification level as a resistance mechanism to osimertinib
@nl
prefLabel
High MET amplification level a ...... post-osimertinib progression.
@en
High MET amplification level as a resistance mechanism to osimertinib
@nl
P2093
P1433
P1476
High MET amplification level a ...... post-osimertinib progression.
@en
P2093
Nikita Agarwal
Sai-Hong Ignatius Ou
Siraj M Ali
P356
10.1016/J.LUNGCAN.2016.05.015
P577
2016-05-25T00:00:00Z